Recruitment Strategies across the Spectrum of Neuronal Synuclein Disease.
Where this comes from
- Record sourced from PubMed, PMID 42108682.
- Also identified by DOI 10.1002/ana.78239.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The Parkinson's Progression Markers Initiative (PPMI) has remained at the vanguard of Parkinson's disease (PD) research through evolving recruitment strategies that mirror advances in PD biology. PPMI was initially focused on untreated, early-stage PD. Over time, it has expanded to include genetic cohorts, prodromal participants identified via olfactory testing and risk factor questionnaires targeting people with rapid eye movement (REM) sleep behavior disorder (RBD). Most recently, PPMI has focused on the biology underlying PD and sought to recruit individuals defined by neuronal alpha-synuclein disease (NSD) biomarkers. This evolution from clinical to biological enrollment demonstrates the feasibility of biomarker-driven cohort design and establishes a scalable model for early detection and prevention research in neurodegenerative disease. ANN NEUROL 2026.